To investigate the role of Annexin A2 (ANXA2) in NLRP3 inflammasome activation and neuronal pyroptosis after intracerebral hemorrhage (ICH), highlighting its potential as a therapeutic target.
Key Findings:
ANXA2 was identified as a prominently upregulated hub protein after ICH.
Co-immunoprecipitation demonstrated a significant association between ANXA2 and NLRP3.
Silencing ANXA2 led to reduced NLRP3 inflammasome activation, decreased GSDMD cleavage, and lower IL-1β/IL-18 secretion.
ANXA2 silencing resulted in improved neurological function and reduced brain injury.
Interpretation:
The study reveals a previously unrecognized ANXA2–NLRP3–pyroptosis pathway in ICH, underscoring ANXA2's critical role in inflammasome regulation and its potential as a therapeutic target.
Limitations:
The study was conducted in a murine model, which may not fully replicate human ICH pathology, and further research is needed to explore the exact mechanisms of ANXA2 in ICH.
Potential confounding factors, such as variations in genetic background or environmental conditions, were not fully addressed.
Conclusion:
ANXA2 is identified as a key neuronal factor associated with NLRP3 inflammasome activation in hemorrhagic stroke, suggesting its potential as a target for therapeutic intervention.
Over two days, specialists across neurology, neurosurgery and related subspecialties came together to discuss advances in stroke care, epilepsy, movement disorders, neurodegenerative disease, neuro-oncology, brain and spine surgery, interventional pain management and emerging technologies.
